Savlon Dry Antiseptic

מדינה: אירלנד

שפה: אנגלית

מקור: HPRA (Health Products Regulatory Authority)

מרכיב פעיל:

Povidone-iodine

זמין מ:

GlaxoSmithKline Consumer Healthcare (Ireland) Limited

קוד ATC:

D08AG; D08AG02

INN (שם בינלאומי):

Povidone-iodine

כמות:

1.14 percent weight/weight

טופס פרצבטיות:

Cutaneous spray, powder

סוג מרשם:

Product not subject to medical prescription

איזור תרפויטי:

Iodine products; povidone-iodine

מצב אישור:

Not marketed

תאריך אישור:

1986-05-12

מאפייני מוצר

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Savlon Dry Antiseptic.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Spray powder containing 1.14% w/w of Povidone Iodine with an available
iodine content of 5% w/w in the powder.
_For full list of excipients, see section 6.1_
3 PHARMACEUTICAL FORM
Cutaneous spray, powder.
Pressurised Cutaneous Spray.
Orange/brown micronised powder and propellants.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
In the topical prophylaxis and treatment of superficial infections or
injuries of skin.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Apply to the affected area by spraying from a distance of 15 to 22 cm.
Special populations;
_Children:_ There are no special dosage recommendations for children.
However, povidone-iodine is not recommended
for regular use in neonates and is contra-indicated in very low birth
weight infants (below 1500g).
_Renal Impairment:_
Avoid regular application to inflammed or broken skin.
4.3 CONTRAINDICATIONS
Savlon Dry is contraindicated in patients with thyroid disorders, in
particular overactive thyroid (hyperthyroidism),
nodular colloid goitre, endemic goitre and Hashimoto’s thyroiditis.
Hypersensitivity to povidone iodine or any other ingredient of the
spray.
Povidone iodine containing products are contra-indicated for preterm
neonates gestational age under 32 weeks.
Use near nose or mouth.
Scheduled radioiodine therapy.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Iodine absorption may interfere with tests of thyroid function.
Application to extensive areas of broken skin may lead to excessive
absorption of iodine.
Regular or prolonged use should be avoided in patients receiving
lithium therapy (refer to section 4.5).
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___